Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 19 June, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Morepen Laboratories Ltd

About the Company - Morepen Laboratories Ltd

No data availabale for About the Company
INDUSTRYADDRESSCONTACT
Industry not foundAddress not foundContact not found
Management Data not Available

Basic Stock Data of Morepen Laboratories Ltd

Last Updated: June 16, 2024, 10:33 pm

Market Cap 2,869 Cr.
Current Price 56.1
High / Low56.4/28.5
Stock P/E29.8
Book Value 16.6
Dividend Yield0.00 %
ROCE16.8 %
ROE12.0 %
Face Value 2.00
PEG Ratio2.00

Competitors of Morepen Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Ami Organics Ltd 5,264 Cr. 1,3971,467/1,00488.4 1830.22 %16.0 %9.39 % 10.0
Brooks Laboratories Ltd 231 Cr. 88.0186/71.5 25.00.00 %24.7 %28.1 % 10.0
Aarti Pharmalabs Ltd 5,404 Cr. 596639/32024.9 1940.34 %16.6 %13.1 % 5.00
Caplin Point Laboratories Ltd 10,624 Cr. 1,3991,619/78123.2 3050.32 %25.2 %23.0 % 2.00
Lincoln Pharmaceuticals Ltd 1,233 Cr. 616755/38613.2 2960.24 %22.5 %17.0 % 10.0
Industry Average15,580.02 Cr1,227.8238.44198.180.35%17.33%16.77%6.56

Morepen Laboratories Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales307287387395396368302403348364401422445
Expenses278256343353364350288374328348375388394
Operating Profit30304442321915292116263451
OPM %10%11%11%11%8%5%5%7%6%4%7%8%11%
Other Income3423331113234
Interest1-00-9110011002
Depreciation8777777777888
Profit before tax2428394727148221411212944
Tax %0%3%21%20%21%13%32%29%36%26%29%26%27%
Net Profit24273037221261698152132
EPS in Rs0.530.590.680.830.480.260.110.310.180.160.290.420.63

Last Updated: April 10, 2024, 4:14 am

Morepen Laboratories Ltd Quarterly Chart

Morepen Laboratories Ltd Profit & Loss

Last Updated: May 30, 2024, 2:32 am

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales2893263674014855956077698531,1881,5471,4181,631
Expenses2702953183524245345427017851,0701,4101,3381,505
Operating Profit19314948626165686911913780126
OPM %7%10%13%12%13%10%11%9%8%10%9%6%8%
Other Income13641-344491210613
Interest8121091084222-723
Depreciation48464639353434403730282831
Profit before tax-24-21-3213243029399912756104
Tax %-0%-0%-0%6%-1%0%0%1%14%1%20%31%
Net Profit-24-21-321324302934971023976
EPS in Rs-0.53-0.46-0.060.050.280.530.660.640.752.162.130.761.50
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Morepen Laboratories Ltd Profit & Loss Yearly Chart

Morepen Laboratories Ltd Growth

Compounded Sales Growth
10 Years:17%
5 Years:17%
3 Years:12%
TTM:19%
Compounded Profit Growth
10 Years:34%
5 Years:27%
3 Years:0%
TTM:149%
Stock Price CAGR
10 Years:28%
5 Years:27%
3 Years:-4%
1 Year:95%
Return on Equity
10 Years:13%
5 Years:15%
3 Years:12%
Last Year:12%

Last Updated: June 17, 2024, 10:00 pm

Morepen Laboratories Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital9090909090909090909096102102
Reserves11190887891106136163194291457651687
Preference Capital1201201201201200000000
Borrowings12111189816816913413213317192528
Other Liabilities225215223240276173226230246460499332377
Total Liabilities5475064904895245385866156638581,0701,1101,194
Fixed Assets452409368322297272264236216225252267287
CWIP0000000002141720
Investments4400000011000
Other Assets9193121167227266321379446631804827886
Total Assets5475064904895245385866156638581,0701,1101,194

Morepen Laboratories Ltd Reserves and Borrowings Chart

Morepen Laboratories Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 27343451504163171151-60-91
Cash from Investing Activity -3-3-1-32-27-14-27-13-12-70-32-47
Cash from Financing Activity -22-30-29-19-27-24-38-054766144
Net Cash Flow214-0-43-14428-266

Morepen Laboratories Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days444442516657736459565968
Inventory Days776856555165766991829687
Days Payable129104116126140125173124113989087
Cash Conversion Cycle-88-17-20-23-3-24937406569
Working Capital Days-25-19-20-18-10-86-62-30-32259104
ROCE %-6%-3%1%3%8%9%9%8%10%25%25%9%

Morepen Laboratories Ltd Financial Efficiency Indicators Chart

Morepen Laboratories Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters34.54%34.54%34.54%38.38%36.74%38.22%38.22%38.22%38.22%38.22%38.22%38.22%
FIIs0.68%0.86%0.91%0.96%0.95%1.15%0.89%0.96%1.00%1.29%2.11%1.85%
DIIs2.05%1.26%1.16%1.07%4.08%3.98%3.74%2.93%2.32%2.27%2.21%2.15%
Government0.00%0.00%0.00%0.00%0.00%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public62.73%63.34%63.39%59.59%58.24%56.63%57.15%57.88%58.45%58.20%57.46%57.76%
No. of Shareholders2,30,6112,44,9242,55,1552,61,4372,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,019

Morepen Laboratories Ltd Shareholding Pattern Chart

No. of Morepen Laboratories Ltd Shareholders

Morepen Laboratories Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF2,8730.150.012,8732024-06-150%

Morepen Laboratories Ltd ROCE Trend

Morepen Laboratories Ltd EPS Trend

Morepen Laboratories Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)1.880.772.262.160.75
Diluted EPS (Rs.)1.880.771.962.160.75
Cash EPS (Rs.)2.541.302.712.831.57
Book Value[Excl.RevalReserv]/Share (Rs.)16.5814.7212.109.436.30
Book Value[Incl.RevalReserv]/Share (Rs.)16.5814.7212.109.436.30
Revenue From Operations / Share (Rs.)33.0727.7332.3726.4118.97
PBDIT / Share (Rs.)3.381.683.082.901.73
PBIT / Share (Rs.)2.721.132.502.230.91
PBT / Share (Rs.)2.651.092.652.190.86
Net Profit / Share (Rs.)1.890.752.132.160.74
NP After MI And SOA / Share (Rs.)1.880.752.132.160.74
PBDIT Margin (%)10.216.049.5010.999.14
PBIT Margin (%)8.234.077.718.444.81
PBT Margin (%)8.013.938.198.294.58
Net Profit Margin (%)5.712.726.578.173.93
NP After MI And SOA Margin (%)5.682.726.578.173.93
Return on Networth / Equity (%)11.345.1317.5722.8511.82
Return on Capital Employeed (%)15.617.3119.4422.0713.16
Return On Assets (%)7.433.489.5011.315.06
Total Debt / Equity (X)0.030.030.030.030.04
Asset Turnover Ratio (%)1.411.301.601.471.24
Current Ratio (X)2.212.351.611.301.06
Quick Ratio (X)1.591.641.000.870.66
Inventory Turnover Ratio (X)3.703.103.534.013.65
Interest Coverage Ratio (X)46.5243.25-19.9673.0239.30
Interest Coverage Ratio (Post Tax) (X)27.0420.53-12.8155.2917.92
Enterprise Value (Cr.)2126.721280.991720.861393.88402.04
EV / Net Operating Revenue (X)1.260.901.111.170.47
EV / EBITDA (X)12.3214.9511.7110.675.15
MarketCap / Net Operating Revenue (X)1.270.921.131.220.50
Price / BV (X)2.541.743.023.401.51
Price / Net Operating Revenue (X)1.270.921.131.220.50
EarningsYield0.040.020.050.060.07

Morepen Laboratories Ltd Profitability Ratios (%)

Morepen Laboratories Ltd Liquidity Ratios

Morepen Laboratories Ltd Liquidity Ratios (%)

Morepen Laboratories Ltd Interest Coverage Ratios (%)

Morepen Laboratories Ltd Valuation Ratios

Fair Value

Fair Value: 60.55

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 7.93% compared to the current price 56.1

Intrinsic Value: 69.55

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 23.98% compared to the current price ₹56.1

Last 5 Year EPS CAGR: 14.87%

*Investments are subject to market risks

Strength and Weakness of Morepen Laboratories Ltd Stock

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 1.90 and average Dividend Yield of 6.65%.
  2. The stock has a low average Working Capital Days of -7.33, which is a positive sign.
  3. The company has higher reserves (241.77 cr) compared to borrowings (46.15 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (361.23 cr) and profit (36.54 cr) over the years.
  1. The stock has a low average ROCE of 8.17%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 11.08, which may not be favorable.

FAQ

What is the latest fair value of Morepen Laboratories Ltd?

The latest fair value of Morepen Laboratories Ltd is ₹60.55.

What is the Market Cap of Morepen Laboratories Ltd?

The Market Cap of Morepen Laboratories Ltd is 2,869 Cr..

What is the current Stock Price of Morepen Laboratories Ltd as on 19 June 2024?

The current stock price of Morepen Laboratories Ltd as on 19 June 2024 is ₹56.1.

What is the High / Low of Morepen Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Morepen Laboratories Ltd stocks is 56.4/28.5.

What is the Stock P/E of Morepen Laboratories Ltd?

The Stock P/E of Morepen Laboratories Ltd is 29.8.

What is the Book Value of Morepen Laboratories Ltd?

The Book Value of Morepen Laboratories Ltd is 16.6.

What is the Dividend Yield of Morepen Laboratories Ltd?

The Dividend Yield of Morepen Laboratories Ltd is 0.00 %.

What is the ROCE of Morepen Laboratories Ltd?

The ROCE of Morepen Laboratories Ltd is 16.8 %.

What is the ROE of Morepen Laboratories Ltd?

The ROE of Morepen Laboratories Ltd is 12.0 %.

What is the Face Value of Morepen Laboratories Ltd?

The Face Value of Morepen Laboratories Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Morepen Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE